Evidence map›Paper›PMID 28892368›Full record

ArticleJournal of the American Chemical Society2017

Structure-Based Design and Synthesis of Apramycin-Paromomycin Analogues: Importance of the Configuration at the 6'-Position and Differences between the 6'-Amino and Hydroxy Series.

Appi Reddy Mandhapati, Guanyu Yang, Takayuki Kato, Dimitri Shcherbakov, Sven N Hobbie, Andrea Vasella, Erik C Böttger, David Crich

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CompleteJournal of the American Chemical Society · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Synthesis, Antibacterial and Antiribosomal Activity of the 3Antibiotics (Basel, Switzerland) · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Real-time measurements of aminoglycoside effects on protein synthesis in live cells.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Appi Reddy MandhapatiDepartment of Chemistry, Wayne State University , Detroit, Michigan 48202, United States.
Guanyu YangDepartment of Chemistry, Wayne State University , Detroit, Michigan 48202, United States.
Takayuki KatoDepartment of Chemistry, Wayne State University , Detroit, Michigan 48202, United States.
Dimitri ShcherbakovInstitute of Medical Microbiology, University of Zurich , 8006 Zurich, Switzerland.
Sven N HobbieInstitute of Medical Microbiology, University of Zurich , 8006 Zurich, Switzerland.
Andrea VasellaOrganic Chemistry Laboratory, ETH Zurich , 8093 Zurich, Switzerland.
Erik C BöttgerInstitute of Medical Microbiology, University of Zurich , 8006 Zurich, Switzerland.
David CrichDepartment of Chemistry, Wayne State University , Detroit, Michigan 48202, United States.ORCID 0000-0003-2400-0083
Wayne State University · USUniversity of Zurich · CHETH Zurich · CH

Funding

Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug-Resistant DiseasesR01AI123352 · NIAID · WAYNE STATE UNIVERSITY · PI CRICH, DAVID · 2016 to 2019
$2.7M
NIAID NIH HHS R01 AI123352
6 · The paper itself

Abstract

The preparation of a series of four analogues of the aminoglycoside antibiotics neomycin and paromomycin is described in which ring I, involved in critical binding interactions with the ribosomal target, is replaced by an apramycin-like dioxabicyclo[4.4.0]octane system. The effect of this modification is to lock the hydroxymethyl side chain of the neomycin or paromomycin ring I, as part of the dioxabicyclooctane ring, into either the gauche-gauche or the gauche-trans conformation (respectively, axial or equatorial to the bicyclic system). The antiribosomal activity of these compounds is investigated with cell-free translation assays using both bacterial ribosomes and recombinant hybrid ribosomes carrying eukaryotic decoding A site cassettes. Compounds substituted with an equatorial hydroxyl or amino group in the newly formed ring are considerably more active than their axial diastereomers, lending strong support to crystallographically derived models of aminoglycoside-ribosome interactions. One such bicyclic compound carrying an equatorial hydroxyl group has activity equal to that of the parent yet displays better ribosomal selectivity, predictive of an enhanced therapeutic index. A paromomycin analog lacking the hydroxymethyl ring I side chain is considerably less active than the parent. Antibacterial activity against model Gram negative and Gram positive bacteria is reported for selected compounds, as is activity against ESKAPE pathogens and recombinant bacteria carrying specific resistance determinants. Analogues with a bicyclic ring I carrying equatorial amino or hydroxyl groups mimicking the bound side chains of neomycin and paromomycin, respectively, show excellent activity and, by virtue of their novel structure, retain this activity in strains that are insensitive to the parent compounds.

Indexed as

Anti-Bacterial AgentsNebramycinNeomycinParomomycinRibosomesAnti-Bacterial AgentsapramycinNebramycinNeomycinParomomycin

Identifiers

PMID28892368
PMCPMC5647259
OpenAlexW2755594177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.